 |
anti-interleukin 21 (NNC0114-0006) in combination with liraglutide |
|---|---|
| Trade Name | |
| Orphan Indication | Type I Diabetes Mellitus with residual beta cell function |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-12 00:00:00 |
| Sponsor | Novo Nordisk, Inc.;800 Scudders Mill Road, P. O. Box 846;New Jersey, 08536 |
